279 related articles for article (PubMed ID: 32061625)
1. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
Packer M
Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
[No Abstract] [Full Text] [Related]
2. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin.
Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jun; 20(6):1367-1368. PubMed ID: 29377537
[No Abstract] [Full Text] [Related]
3. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer M
Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
[No Abstract] [Full Text] [Related]
4. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
5. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
6. Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020.
Hirsch IB; Gaudiani LM
JAMA; 2020 Jun; 323(23):2419-2420. PubMed ID: 32442246
[No Abstract] [Full Text] [Related]
7. Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.
Packer M
Cardiovasc Diabetol; 2020 May; 19(1):62. PubMed ID: 32404204
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
[No Abstract] [Full Text] [Related]
9. First-line treatment for type 2 diabetes: is it too early to abandon metformin?
Zaccardi F; Khunti K; Marx N; Davies MJ
Lancet; 2020 Nov; 396(10264):1705-1707. PubMed ID: 33248483
[No Abstract] [Full Text] [Related]
10. Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis.
Wong HJ; Lin NH; Teo YN; Syn NL; Teo YH; Sia CH
Am J Cardiovasc Drugs; 2024 May; 24(3):371-383. PubMed ID: 38589722
[TBL] [Abstract][Full Text] [Related]
11. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
Vaduganathan M; Januzzi JL
Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
[TBL] [Abstract][Full Text] [Related]
12. Metformin in patients with type 2 diabetes mellitus and heart failure: a review.
Kułaczkowska ZM; Wróbel M; Rokicka D; Gąsior M; Strojek K
Endokrynol Pol; 2021; 72(2):163-170. PubMed ID: 33970481
[TBL] [Abstract][Full Text] [Related]
13. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
Verburg AFE; van den Donk M; Wiersma T
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
[TBL] [Abstract][Full Text] [Related]
14. [DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes].
Paquot N; Scheen AJ
Rev Med Suisse; 2017 Aug; 13(571):1410-1415. PubMed ID: 28837277
[TBL] [Abstract][Full Text] [Related]
15. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest.
Patoulias D; Papadopoulos C; Katsimardou A; Doumas M
Am J Cardiol; 2021 Jan; 139():134-136. PubMed ID: 33075281
[No Abstract] [Full Text] [Related]
17. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
19. Urinary α1 microglobulin level is useful for selecting sodium-glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes.
Koshizaka M; Ishibashi R; Ishikawa K; Shoji M; Ide K; Ide S; Kato H; Teramoto N; Terayama R; Maezawa Y; Yokote K;
Diabetes Obes Metab; 2023 Oct; 25(10):3071-3075. PubMed ID: 37385959
[No Abstract] [Full Text] [Related]
20. The position of SGLT2 inhibitors in current medicine.
Prázný M
Vnitr Lek; 2020; 66(2):82-88. PubMed ID: 32942881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
